View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 16, 2021

LoA Update: BMS’ Opdivo/relatlimab combination gets boost in approval likelihood in 1L melanoma after Phase II/III results at ASCO

The Likelihood of Apporval (LoA) for Bristol Myers Squibb’s Opdivo (nivolumab) combo with the anti-LAG3 antibody relatlimab climbed by 10 points to 49%, as of 9 June.

By Manasi Vaidya

The Likelihood of Apporval (LoA) for Bristol Myers Squibb’s Opdivo (nivolumab)  combo with the anti-LAG3 antibody relatlimab climbed by 10 points to 49%, as of 9 June. The change was due to Phase II/III study results presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting last week.

The Phase II/III study evaluated the ability of Opdivo and relatlimab administered as a single infusion, compared to Opdivo alone to treat previously untreated metastatic or unresectable melanoma.  The median progression-free survival (PFS) for the combination was 10.1 months compared to 4.6 months with Opdivo alone (hazard ratio=0.75; p=0.0055), as per a presentation on 6 June. Opdivo is currently approved to treat unresectable or metastatic melanoma either as a monotherapy or in combination with BMS’ anti-CTLA-4 antibody Yervoy (ipilimumab), and as an adjuvant therapy in certain settings in melanoma. The company will discuss Opdivo/relatlimab data with regulatory authorities to make the treatment available to patients, as per 19 May press release, but did not provide timelines. Relatlimab is estimated to earn $477m in 2027, as per GlobalData consensus forecasts. BMS’ market cap is $150.36bn.

Prior to the data release at ASCO, the combination’s LoA was 39%. The LoA is calculated by using a combination of machine learning and a proprietary algorithm, and considers characteristics like therapy area, indication and molecule type.

Manasi Vaidya is a Associate Editor for Pharmaceutical Technology parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena